Hospital Acquired Infection (HAI) Control Markets

 
   Single User - $4,500
   Site License (one location, 10 users) - $6,750
   Corporate License - $9,000



Loading...
Published Feb 22, 2017 | 242 Pages | Pub ID: KLI15261546

Hospital Acquired Infection (HAI) Control Markets

Hospital Acquired Infection (HAI) Control Markets focuses on the market for preventing, testing, and treating infections in the healthcare environment. Major consideration is given to bacterial nosocomial infections because they are the most frequent type of infections spread in the healthcare delivery setting and the practical aspects of diagnosis and therapy are more meaningful based on a combination of medical and financial considerations. The report provides a market analysis for each of three areas: prevention (sterilization and disinfection equipment), testing, and treatment, detailing the following market data:
  • The Global Market for Hospital Infection Control, 2010-2021
  • The Global Market for Hospital Infection Prevention Equipment and Consumables (Sterilization/Disinfection), 2010-2021
  • The Global Market for Hospital Infection Prevention (Sterilization/Disinfection) Estimated Products Sales by Primary Geographic Region, 2010-2021 (United States, Europe, Rest of World, Total)
  • Market Value for Infection Prevention Equipment and Related Consumables by Product Type, 2016 (Medical Device/Instrument Sterilization, Wide-Area/Room Sterilization, Medical-grade Disinfection Solutions, Other Products, Total)
  • Market Value for Infection Prevention Equipment and Related Consumables by Technology, 2016 (Heat/Steam, Gas/Chemical, Ultrasound, Other, Total)
  • The Global Market for Hospital Infection Prevention (Sterilization/Disinfection), Leading Suppliers’ Shares, Estimates for 2016
  • The Global Market for Hospital Infection Testing/Diagnostics, 2010-2021
  • The Global Market for Hospital Infection Testing/Diagnostics, Estimated Products Sales by Primary Geographic Region, 2010-2021 (United States, Europe, Rest of World, Total)
  • The Global Market for Hospital Infection Testing/Diagnostics Leading Suppliers’ Shares Estimates for 2016
  • The Global Market for Hospital Infection Treatment, 2010-2021
  • The Global Market for Hospital Infection Treatment Estimated Products, Sales by Primary Geographic Region, 2010-2021 (United States, Europe, Rest of World, Total)
  • The Global Market for Hospital Infection Treatment, Leading Suppliers' Shares, Estimated Share for HAIs for 2016
  • Annual Sales of Select Antibacterial Products, 2016
  • The Global Market for Hospital Infection Control, Estimated Market Share by Segment, 2016 (Treatment, Prevention, Testing)
  • The Global Market for Hospital Infection Control Estimated Market Share by Facility Setting, 2016 (Hospitals, Outpatient Servicing Centers, Dialysis Centers, Nursing Homes, Community Clinics, Others)
  • The Global Market for Hospital Infection Control Estimated Market Share by Hospital Department, 2016 (ICU, Med/Surg, Pediatrics, Others)
  • The Global Market for Hospital Infection Control, Estimated Products Sales by Primary Geographic Region, 2010-2021 (United States, Europe, Rest of World, Total)
  • The Global Market for Hospital Infection Control, Estimated Product Sales by Geographic Region, 2010-2021 (United States, Europe, Rest of World)
  • The Global Market for Hospital Infection Control, Estimated Market Share by Geographic Region, 2016 (%) (United States, Europe, Rest of World)
  • The Global Market for Hospital Infection Control, Estimated Market Share by Region, 2016 (%) (Developed Europe, Emerging Europe, United States, Rest of World [Japan, India, Canada, Brazil, China, Mexico, Africa, Other Developed, Other Emerging])
  • Global Markets for HAI by Participant and Segment (Infection Prevention, Infection Diagnostics, Infection Treatment)
A nosocomial infection is a new infection that develops in a patient during hospitalization or during a stay at a health facility. It is usually defined as an infection that is identified at least forty-eight to seventy-two hours following admission, so infections incubating, but not clinically apparent, at admission are excluded. This type of infection is also known as a hospital-acquired infection (or, more generically, healthcare associated infection). The report provides the following data regarding nosocomial infections:
  • Frequency of the Most Common Nosocomial Infections
  • Market Value for Nosocomial Infection Diagnostics by Class, 2016 (Immunoassays, Microbial Identification / Antimicrobial Sensitivity (ID/AST), Molecular DNA, Total)
  • Market Value for Nosocomial Infection Diagnostics by Pathogen Target, 2016 (C. difficile Infections; MRSA Infections; Enterococcus, vancomycin-resistant; Enterobacteriaceae, carbapenem-resistant; M Tuberculosis; Others; Total)
  • Market Value for Nosocomial Infection Treatments by Class, 2016 (Quinolones, Glycopeptides, ß-lactamase inhibitors, Tetracyclines, Oxazolidinones, Macrolides, Carbapenems, Cephalosporins, Penicillins, Combinations, Others, Total)
  • Nosocomial Infection Drug Candidates by Class, 2016 (Quinolones, Glycopeptides, Aminoglycosides, Tetracyclines, Oxazolidinones, Macrolides, Pleuromutilins, Cephalosporins, Fabl inhibitors, Combinations, Others, Total)
  • Market Value for Nosocomial Infection Treatments by Pathogen Target, 2016 (ABSSSI, cUTI, MRSA Infections, HAP/VAP, C. Difficile Infections, Others, Total)
Hospital acquired infections share many of the challenges faced by the larger healthcare industry. Both challenges and industry trends are discussed in Hospital Acquired Infection (HAI) Control Markets, as well as market growth drivers and market growth inhibitors. One of the challenges facing the market is that increased attention to identification in the emergency department (ED) is needed to reduce risk and control exposure. With rapid identification, placing patients in isolation, whether they are colonized or infected, will likely make a difference in the resistance rates and spread of microorganisms in hospitalized patients.

The majority of competitive participation for healthcare infection control is in the United States and Europe. However, competition is steadily escalating in these areas, which is encouraging more participation in other regions such as Asia and Latin America. The report profiles important players in the current competitive landscape, including:
  • 3M
  • Abbott Laboratories
  • AbbVie
  • Advanced Sterilization Products
  • Alere
  • AstraZeneca
  • Bayer
  • Becton, Dickinson
  • Belimed
  • bioMérieux
  • Cantel Medical
  • Danaher
  • Ecolab
  • Getinge AB
  • GlaxoSmithKline
  • Merck & Co.
  • Pfizer, Inc.
  • Roche (F. Hoffman-La Roche, Ltd.)
  • Sakura Seiki, Co., Ltd.
  • Steris plc
  • TSO3
Market analysis in this report considers primarily the epidemiological considerations and the size of patient groups both in the United States and globally, where available. We have accumulated the most recent data available, understanding that virtually no organization does extensive studies on these applications on a regular basis. Many studies are highly localized and may only apply to a community, state or country (more often countries that are not a part of the major markets for nosocomial diagnostic and therapeutic products). In many instances, we have had to draw from broader epidemiologic data, that is, on data that reach outside of the hospital and primary care environment in order to construct a picture of the infection prevention, testing and treatment needs.
In this report,  {{key}} appears {{searchResults.reportMatchCounts[value]}} times
We were unable to search inside this report.
No results matched your search criteria.

Search for an exact word or phrase by placing the word or phrase in quotation marks ("market trend"). Search for different versions or tenses of a word by placing an asterisk at the end of the word (pharma*).

Please note that your term must be at least three characters long and numbers will be blocked by the # sign.